US5550118A - Polyhydronorharman synthase inhibitors - Google Patents
Polyhydronorharman synthase inhibitors Download PDFInfo
- Publication number
- US5550118A US5550118A US08/189,213 US18921394A US5550118A US 5550118 A US5550118 A US 5550118A US 18921394 A US18921394 A US 18921394A US 5550118 A US5550118 A US 5550118A
- Authority
- US
- United States
- Prior art keywords
- compound
- polyhydronorharman
- compounds
- synthase
- carboline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003112 inhibitor Substances 0.000 title description 3
- 230000002378 acidificating effect Effects 0.000 claims abstract description 10
- 125000005647 linker group Chemical group 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 87
- 239000000203 mixture Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000000651 prodrug Chemical class 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- -1 aliphatic ester Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 210000001772 blood platelet Anatomy 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000012453 solvate Chemical class 0.000 claims description 6
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- RIFJROSABFCJNR-UHFFFAOYSA-N ethyl 6-(6,7,8,9-tetrahydro-5h-pyrido[3,4-b]indol-1-yl)hexanoate Chemical compound C1CCCC2=C1C(C=CN=C1CCCCCC(=O)OCC)=C1N2 RIFJROSABFCJNR-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- JGJQEGSBJPUMQW-UHFFFAOYSA-N ethyl 5-(6,7,8,9-tetrahydro-5h-pyrido[3,4-b]indol-1-yl)pentanoate Chemical compound C1CCCC2=C1C(C=CN=C1CCCCC(=O)OCC)=C1N2 JGJQEGSBJPUMQW-UHFFFAOYSA-N 0.000 claims description 2
- UNXOHKYUAZVMCV-UHFFFAOYSA-N ethyl 7-(6,7,8,9-tetrahydro-5h-pyrido[3,4-b]indol-1-yl)heptanoate Chemical compound C1CCCC2=C1C(C=CN=C1CCCCCCC(=O)OCC)=C1N2 UNXOHKYUAZVMCV-UHFFFAOYSA-N 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 101100177155 Arabidopsis thaliana HAC1 gene Proteins 0.000 claims 1
- 101100434170 Oryza sativa subsp. japonica ACR2.1 gene Proteins 0.000 claims 1
- 101100434171 Oryza sativa subsp. japonica ACR2.2 gene Proteins 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 12
- 239000003768 thromboxane synthase inhibitor Substances 0.000 abstract description 7
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 abstract 1
- 101150035983 str1 gene Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 10
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002399 angioplasty Methods 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 5
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 4
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 4
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 4
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 4
- YUWOLBZMQDGRFV-UHFFFAOYSA-N 3-nitro-1h-pyridin-4-one Chemical compound [O-][N+](=O)C1=CNC=CC1=O YUWOLBZMQDGRFV-UHFFFAOYSA-N 0.000 description 4
- JOTRPRKONYTVBV-UHFFFAOYSA-N 4-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CN=CC=C1Cl JOTRPRKONYTVBV-UHFFFAOYSA-N 0.000 description 4
- XLUKCVDNZMRJNM-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-pyrido[3,4-b]indole Chemical compound N1C2=CN=CC=C2C2=C1CCCC2 XLUKCVDNZMRJNM-UHFFFAOYSA-N 0.000 description 4
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- LIRSBJIZLKCUQH-UHFFFAOYSA-N 2-(2-nitropyridin-4-yl)cyclohexan-1-one Chemical compound C1=NC([N+](=O)[O-])=CC(C2C(CCCC2)=O)=C1 LIRSBJIZLKCUQH-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000003938 Thromboxane Receptors Human genes 0.000 description 3
- 108090000300 Thromboxane Receptors Proteins 0.000 description 3
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 description 3
- 229940111979 Thromboxane synthase inhibitor Drugs 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960000103 thrombolytic agent Drugs 0.000 description 3
- 239000002396 thromboxane receptor blocking agent Substances 0.000 description 3
- LPANXHVMGMWJRZ-UHFFFAOYSA-N 6-(6,7,8,9-tetrahydro-5h-pyrido[3,4-b]indol-1-yl)hexanoic acid;hydrochloride Chemical compound Cl.C1CCCC2=C1C(C=CN=C1CCCCCC(=O)O)=C1N2 LPANXHVMGMWJRZ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical class N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- ZAJJJOMMWPVJMH-UHFFFAOYSA-N 3-carbazol-9-ylpropanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)C3=CC=CC=C3C2=C1 ZAJJJOMMWPVJMH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000015846 Prostacyclin synthases Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LTWOHZNXCOUWKH-UHFFFAOYSA-N ethyl 6-iodohexanoate Chemical compound CCOC(=O)CCCCCI LTWOHZNXCOUWKH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- FMTPMKQBULAOOR-UHFFFAOYSA-N nitric acid;1h-pyridin-4-one Chemical compound O[N+]([O-])=O.O=C1C=CNC=C1 FMTPMKQBULAOOR-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108010064377 prostacyclin synthetase Proteins 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229950007952 vapiprost Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Definitions
- This invention concerns norharman compounds useful as thromboxane synthase inhibitors.
- the tricyclic compound, norharman (CA Registry No. 244-63-3), is also known as beta-carboline; carbazoline; 2-azacarbazole; 2,9-diazafluorene; and 9H-pyrido (3,4- ⁇ ) indole.
- U.S. Pat. No. 5,066,649 describes various 8,9-annelated 1,2,3,4-tetrahydro-beta-carbolines as orally active fibrinolytics.
- Therapeutic agents for specifically reducing the production of thromboxane A 2 are useful for treatment of conditions such as renal disease, (e.g., hydronephrosis, transplant rejection, and renal nephritis) pulmonary disease, (e.g., asthma, and pulmonary hypertension), prevention and treatment of hepatic and intestinal damage, cardiovascular diseases (e.g., arteriosclerosis, thrombosis, hypertension, and shock) or resulting from surgical procedures such as angioplasty and coronary bypass surgery.
- Aspirin has utility as a nonspecific indirect inhibitor of thromboxane synthesis; however, it is desirable to discover new compounds having more potent and specific TSI properties than aspirin.
- This invention is a novel series of polyhydronorharman type compounds which inactivate TXA 2 synthase in human blood platelets and other cells, said compounds having the general structural formula (I): ##STR2##
- This invention is also a pharmaceutical formulation containing as active ingredient the polyhydronorharman compounds of formula (I); where R 1 , R 2 , n, m, L a , A, B 5 , B 6 , B 7 and B 8 are as hereinafter defined.
- This invention is also a multi-component pharmaceutical composition
- thrombolytic agents comprising the polyhydronorharman compound of the invention together with thrombolytic agents, angiotensin converting enzyme inhibitors, and/or thromboxane receptor antagonists.
- This invention is a method of inhibiting thromboxane production by giving a mammal a therapeutically effective dose of a compound of the invention.
- This invention is also an improved method of conducting surgical operations such as angioplasty and bypass surgery by administration to the patient a therapeutically effective dose of a compound of the invention.
- This invention relates to new thromboxane synthase inhibitors, and their use as antithrombotic agents for prophylaxis and treatment of thromboembolic diseases such as venous thrombosis, pulmonary embolism, arterial thrombosis, in particular myocardial ischemia, myocardial infarction and cerebral thrombosis, general hypercoagulable states and local hypercoagulable states such as following angioplasty and coronary bypass operations, and generalized tissue injury as it relates to the inflammatory process.
- thromboembolic diseases such as venous thrombosis, pulmonary embolism, arterial thrombosis, in particular myocardial ischemia, myocardial infarction and cerebral thrombosis, general hypercoagulable states and local hypercoagulable states such as following angioplasty and coronary bypass operations, and generalized tissue injury as it relates to the inflammatory process.
- halo means a radical derived from fluorine, chlorine, bromine, or iodine.
- alkyl by itself or as part of another substituent, unless otherwise stated means a straight or branched chain alkyl radical having the stated number of carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and tertiary-butyl.
- aryl refers to an organic radical derived from an aromatic hydrocarbon by removal of one atom; e.g., phenyl, and naphthyl.
- substituted phenyl means a phenyl radical substituted at one or more positions by one or more acyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, halo, nitro, sulfo, amino, or hydroxyl groups.
- acidic group refers to an organic radical which is a proton donor.
- an effective amount means an amount of the compound of the invention which is capable of inactivating TXA 2 synthase in human blood platelets and other cells to an extent which achieves a beneficial therapeutic and/or prophylactic result.
- salts include both acid and base addition salts.
- chain atoms means the number of atoms in the shortest chain between the two bonds of the linking group --(L a )--.
- the presence of a benzene or cyclohexane ring in the shortest chain counts as two atoms.
- the linking groups (a) and (b); ##STR3## have 5 and 7 chain atoms, respectively.
- novel compounds of the invention are represented by Formula (I) or a pharmacologically acceptable salt or prodrug thereof: ##STR4##
- n is an integer from 4 to 8;
- B 5 , B 6 , B 7 , and B 8 are selected from the group consisting of carbon, nitrogen, oxygen, and sulfur with the proviso that at least two of B 5 , B 6 , B 7 , or B 8 are carbon;
- R 1 is a radical at position 5, 6, 7, and 8 where each R 1 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 4 -C 8 cycloalkyl, C 1 -C 12 halogenated alkyl, C 1 -C 12 hydroxylated alkyl, C 1 -C 12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkylthio, acyl, C 1 -C 6 alkoxy, or
- R 2 is a radical at position 1, 3 or 4 where each R 2 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 4 -C 8 cycloalkyl, C 1 -C 12 halogenated alkyl, C 1 -C 12 hydroxylated alkyl, C 1 -C 12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkylthio, acyl, C 1 -C 6 alkoxy, or C
- (L a ) is a divalent linking group
- A is an acidic group.
- Preferred compounds of the invention are those wherein each R 1 is hydrogen and/or each R 2 is hydrogen.
- R 4 is selected from hydrogen, C 1 -C 12 alkyl, phenyl or substituted phenyl.
- divalent linking group --(L a )-- has from 4 to 8 chain atoms and most preferably 5 or 6 chain atoms.
- divalent linking group, --(L a )-- is selected from the following formulae: ##STR7##
- Formula (I) polyhydronorharman compounds which inactivate TXA 2 synthase in human blood platelets and other cells is represented by Formula (II) and pharmacologically acceptable salts, solvates, or prodrugs thereof; ##STR8## wherein;
- R 1 is a radical at position 5, 6, 7, and 8 where each R 1 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 4 -C 8 cycloalkyl, C 1 -C 12 halogenated alkyl, C 1 -C 12 hydroxylated alkyl, C 1 -C 12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkylthio, acyl, C 1 -C 6 alkoxy, or
- R 2 is a radical at position 1, 3 or 4 where each R 2 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 4 -C 8 cycloalkyl, C 1 -C 12 halogenated alkyl, C 1 -C 12 hydroxylated alkyl, C 1 -C 12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkylthio, acyl, C 1 -C 6 alkoxy, or C
- (L a ) is a divalent linking group containing from 4 to 6 chain atoms
- A is an acidic group.
- Preferred compounds of formula (II) are those wherein each R 1 is hydrogen and/or each R 2 is hydrogen, and A is carboxyl.
- Formula (II) polyhydronorharman compounds which inactivate TXA 2 synthase in human blood platelets and other cells is represented by Formula (III) and pharmacologically acceptable salts or prodrugs thereof. ##STR9## wherein;
- p is an integer 4 or 5.
- the compounds of the invention possess at least one acidic functional substituent (viz., group A of Formula I) and, as such, are capable of forming salts.
- Representative pharmaceutically acceptable salts include but are not limited to, the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion exchange resin.
- salts include the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Phar. Sci., 66: 1-19 (1977)).
- the compounds of the invention may be reacted with suitable organic or inorganic acids to form salts such as acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, chloride, edetate, edisylate, estolate, esylate, fluoride, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, bromide, chloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, malseate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, ole
- the compounds of the formula (I) can also be in the form of zwitterions, since they contain both acidic and basic functionality and are capable of self-protonation.
- Certain compounds of the invention possess one or more chiral centers and may thus exist in optically active forms. Likewise, when the compounds contain an alkenyl or alkenylene group there exists the possibility of cis- and trans- isomeric forms of the compounds.
- the R- and S- isomers and mixtures thereof, including racemic mixtures as well as mixtures of cis- and trans- isomers, are contemplated by this invention. Additional asymmetric carbon atoms can be present in a substituent group such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the invention.
- a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods.
- Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in fly. Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
- Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine.
- Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs.
- double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters.
- This invention also provides pharmaceutical formulations comprising a novel compound as described in the preceding Section I or a pharmaceutically acceptable salt or prodrug thereof.
- any suitable carrier known in the art can be used.
- the carrier may be a solid, liquid, or mixture of a solid and a liquid.
- Solid form formulations include powders, tablets and capsules.
- a solid carrier can be one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
- the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
- the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel compound of this invention.
- Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa butter.
- Sterile liquid form formulations include suspensions, emulsions, syrups and elixirs.
- the active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both.
- a pharmaceutically acceptable carrier such as sterile water, sterile organic solvent or a mixture of both.
- the active ingredient can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol.
- suitable organic solvent for instance aqueous propylene glycol.
- Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
- the pharmaceutical formulation is in unit dosage form.
- the unit dosage form can be a capsule or tablet itself, or the appropriate number of any of these.
- the quantity of active ingredient in a unit dose of composition may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration.
- formulations according to the invention may be made for oral, parenteral or rectal administration or in a form suitable for administration by inhalation or insufflation, either through the mouth or nose.
- Active ingredient refers to a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- Hard gelatin capsules are prepared using the following ingredients:
- a tablet is prepared using the ingredients below:
- the components are blended and compressed to form tablets each weighing 665 mg
- An aerosol solution is prepared containing the following components:
- the active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30° C. and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.
- Tablets each containing 60 mg of active ingredient, are made as follows:
- the active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
- the aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve.
- the granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. sieve.
- the sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
- Capsules each containing 80 mg of active ingredient, are made as follows:
- the active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
- Suppositories each containing 225 mg of active ingredient, are made as follows:
- the active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.
- Suspensions each containing 50 mg of active ingredient per 5 ml dose, are made as follows:
- the active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste.
- the benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
- An intravenous formulation may be prepared as follows:
- the solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute.
- the pharmaceutical formulations of the invention inactivate TXA 2 synthase in human blood platelets and other cells.
- an Active Ingredient for multi-mode pharmaceutical formulations
- an Active Ingredient may be formed by combining the compounds of this invention (as represented by Formulae I, II, and III) with therapeutic agents selected from one or more of the following classes:
- thrombolytic agents are tissue plasminogen activator (t-PA) and streptokinase. These agents would be preferably used in combination with the compounds of the invention for cardiovascular indications.
- Angiotensin converting enzyme inhibitors (b) such as captopril, (1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline would be preferably used in combination with the compounds of the invention for renal indications such as diabetic nephropathy.
- thromboxane receptor antagonists examples include Vapiprost (Glaxo) and S-1452TM compound (CAS Reg. No.132747-47-8); (5-Heptanoic acid, 7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-calcium salt (2:1), [1R-[1 ⁇ ,2 ⁇ (Z),3 ⁇ ,4 ⁇ ]]; and VAPIPROSTTM compound (CAS Reg. No.
- Combinations of the compounds of the invention with thromboxane receptor antagonist is a preferred aspect of this invention, because the (TRA) blocks the activity of prostaglandin H 2 which is enhanced by the thromboxane synthase inhibitor compounds of the invention (represented by formulae I, II, and III).
- the relative proportions of ingredients will generally be in the range of from 1 to 1000 to 1000 to 1 and is readily determined by combining dosages of the ingredients in weights known to be pharmaceutically effective.
- Multi-mode pharmaceutical composition may be formed by admixing the compounds of the invention with one or more classes of therapeutic agent (a), (b), or (c) listed above.
- each ingredient, (i) the compound of the invention, and (ii) the selected therapeutic agent may be packaged together, for example in a tablet having two parts, so their administration to the patient is concurrent.
- This invention is a method for inhibiting thromboxane production which comprises administering to a mammalian host (e.g. human) an effective amount of the novel compounds for formulae (I), (II), or (III).
- a mammalian host e.g. human
- the treatment of a mammal with the compounds of the invention may be for either therapeutic and/or prophylactic purposes.
- a preferred method of the invention for inhibiting thromboxane production is administration to a mammal of the pharmaceutical formulations of the invention described in Section II, above, or the multi-mode pharmaceutical formulations described in Section III, above.
- a specific dose of a compound of the invention administered to obtain therapeutic and/or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the route of administration and the condition being treated.
- a typical daily dose will contain a non-toxic dosage level of compound of from about 0.01 mg/kg to about 50 mg/kg of body weight.
- Preferred daily doses generally will be from about 0.05 mg/kg to about 20 mg/kg.
- This invention is also an improved method of conducting angioplasty by administering before and/or during the angioplasty the thrombosis preventing novel compounds of formulae (I), (II) or (III).
- This invention is a method for the prevention or treatment of a first or recurrent myocardial infarction or a first or recurrent stroke in a human comprising administering to the human in an amount effective for prevention or treatment of a first or recurrent myocardial infarction for first or recurrent stroke, a combination of active ingredients comprising the compounds of formulae (I), (II) or (III) or a pharmaceutically acceptable salt or prodrug thereof.
- Scheme 1 is an illustrative reaction sequence for preparation of 5,6,7,8-tetrahydro- ⁇ -carboline-1-alkanoic acids.
- Fuming nitric and sulfuric acids are employed to nitrate 4-hydroxypyridine to produce 4-hydroxy-3-nitropyridine.
- the 4-hydroxy-3-nitropyridine is converted to 4-chloro-3-nitropyridine by heating with PC 15 and POCl 3 .
- reaction solution was then stirred at room temperature under nitrogen for 3.5 hours before it was added to ice water (100 ml) and extracted with ethyl acetate (2 ⁇ 75 ml). The combined organic phases were washed with brine (35 ml), dried (MgSO 4 ), and concentrated in vacuo to a brown oil. Chromatography provided 0.58 g (43%) desired product as yellow oil.
- TSI Thromboxane Synthase Inhibition
- test compound 5,6,7,8-tetrahydro- ⁇ -carboline-1-hexanoic acid hydrochloride salt, (the compound of Example 1, Part F) was dissolved in dimethylsulfoxide at varying concentrations.
- the compound solutions and dimethylsulfoxide alone were incubated with fresh whole human blood that had been anticoagulated with 0.38% trisodium citrate, for 30 minutes at 37° C.
- 0.025 ml of 0.5M calcium chloride solution was added to each 1 ml of blood and further incubated for one hour at 37° C. Serum was prepared by centrifugation of the blood at 2000 ⁇ g for 15 minutes in a Beckman table top centrifuge.
- the oral activity of the compound of Example 1, Part P was established by treating rats via the oral route with solutions of the compound and one hour later collecting blood.
- the blood was allowed to clot in glass tubes for 1 hour at 37° C.
- Serum was collected after sedimentation of the clot by centrifugation at 2000 ⁇ g for 15 minutes in a Beckman table top centrifuge.
- the levels of TXB 2 were measured in the serum by radioimmunoassay. Decreased levels of TXB 2 indicate the presence of compound in the blood resulting from oral absorption.
- Table 3 The results of these experiments are shown in Table 3 and document the availability of the compound by the oral route of administration and the dose-dependency of the desired inhibitory effect on serum TXB 2 .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Selected acid functional polyhydronorharman type derivatives effective as thromboxane synthase inhibitors having the formula: ##STR1## where R1 and R2 are monovalent radicals, --(La)-- is a linking group of 4 to 8 chain atoms, and A is an acidic group.
Description
This invention concerns norharman compounds useful as thromboxane synthase inhibitors.
The tricyclic compound, norharman (CA Registry No. 244-63-3), is also known as beta-carboline; carbazoline; 2-azacarbazole; 2,9-diazafluorene; and 9H-pyrido (3,4-β) indole.
The preparation of certain esters of 9-pyrido(3,4-β)indole alkanoic acids is described in U.S. Pat. No. 2,850,501.
U.S. Pat. No. 5,066,649 describes various 8,9-annelated 1,2,3,4-tetrahydro-beta-carbolines as orally active fibrinolytics.
Therapeutic agents for specifically reducing the production of thromboxane A2 are useful for treatment of conditions such as renal disease, (e.g., hydronephrosis, transplant rejection, and renal nephritis) pulmonary disease, (e.g., asthma, and pulmonary hypertension), prevention and treatment of hepatic and intestinal damage, cardiovascular diseases (e.g., arteriosclerosis, thrombosis, hypertension, and shock) or resulting from surgical procedures such as angioplasty and coronary bypass surgery. Aspirin has utility as a nonspecific indirect inhibitor of thromboxane synthesis; however, it is desirable to discover new compounds having more potent and specific TSI properties than aspirin.
This invention is a novel series of polyhydronorharman type compounds which inactivate TXA2 synthase in human blood platelets and other cells, said compounds having the general structural formula (I): ##STR2##
This invention is also a pharmaceutical formulation containing as active ingredient the polyhydronorharman compounds of formula (I); where R1, R2, n, m, La, A, B5, B6, B7 and B8 are as hereinafter defined.
This invention is also a multi-component pharmaceutical composition comprising the polyhydronorharman compound of the invention together with thrombolytic agents, angiotensin converting enzyme inhibitors, and/or thromboxane receptor antagonists.
This invention is a method of inhibiting thromboxane production by giving a mammal a therapeutically effective dose of a compound of the invention.
This invention is also an improved method of conducting surgical operations such as angioplasty and bypass surgery by administration to the patient a therapeutically effective dose of a compound of the invention.
This invention relates to new thromboxane synthase inhibitors, and their use as antithrombotic agents for prophylaxis and treatment of thromboembolic diseases such as venous thrombosis, pulmonary embolism, arterial thrombosis, in particular myocardial ischemia, myocardial infarction and cerebral thrombosis, general hypercoagulable states and local hypercoagulable states such as following angioplasty and coronary bypass operations, and generalized tissue injury as it relates to the inflammatory process.
The following terms, have the definitions set out below:
The term "halo means a radical derived from fluorine, chlorine, bromine, or iodine.
The term "alkyl" by itself or as part of another substituent, unless otherwise stated means a straight or branched chain alkyl radical having the stated number of carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and tertiary-butyl.
The term "aryl" as used herein refers to an organic radical derived from an aromatic hydrocarbon by removal of one atom; e.g., phenyl, and naphthyl.
The term "substituted phenyl" means a phenyl radical substituted at one or more positions by one or more acyl, C1 -C6 alkyl, C2 -C6 alkenyl, C2 -C6 alkynyl, C1 -C6 alkoxy, halo, nitro, sulfo, amino, or hydroxyl groups.
The term "acidic group" refers to an organic radical which is a proton donor.
The term "effective amount" as used herein, means an amount of the compound of the invention which is capable of inactivating TXA2 synthase in human blood platelets and other cells to an extent which achieves a beneficial therapeutic and/or prophylactic result.
The words "pharmacologically acceptable salts" include both acid and base addition salts.
The words "chain atoms" means the number of atoms in the shortest chain between the two bonds of the linking group --(La)--. The presence of a benzene or cyclohexane ring in the shortest chain counts as two atoms. For example, the linking groups (a) and (b); ##STR3## have 5 and 7 chain atoms, respectively.
The novel compounds of the invention are represented by Formula (I) or a pharmacologically acceptable salt or prodrug thereof: ##STR4##
The dashed line in formula (I) above indicates optional unsaturation, namely, of one or no double bonds in the ring having the B5, B6, B7 and B8 atoms. Formula (I) represents any of structures Ia thru Id below. The unsaturation, in the case of one optional double bond being present results in structures Ia thru Ic depicted below. No optional double bond results in structure Id, below. ##STR5## and wherein;
n is an integer from 4 to 8;
B5, B6, B7, and B8 are selected from the group consisting of carbon, nitrogen, oxygen, and sulfur with the proviso that at least two of B5, B6, B7, or B8 are carbon;
R1 is a radical at position 5, 6, 7, and 8 where each R1 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 alkoxy, C4 -C8 cycloalkyl, C1 -C12 halogenated alkyl, C1 -C12 hydroxylated alkyl, C1 -C12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C1 -C6 alkenyl, C1 -C6 alkynyl, C1 -C6 alkylthio, acyl, C1 -C6 alkoxy, or C1 -C6 alkylsulfonyl;
R2 is a radical at position 1, 3 or 4 where each R2 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 alkoxy, C4 -C8 cycloalkyl, C1 -C12 halogenated alkyl, C1 -C12 hydroxylated alkyl, C1 -C12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C1 -C6 alkenyl, C1 -C6 alkynyl, C1 -C6 alkylthio, acyl, C1 -C6 alkoxy, or C1 -C6 alkylsulfonyl;
(La) is a divalent linking group; and
A is an acidic group.
Preferred compounds of the invention are those wherein each R1 is hydrogen and/or each R2 is hydrogen.
Preferred are compounds of formula (I) wherein the acidic group A is selected from the following:
--5-tetrazolyl,
--SO3 H
--carboxyl ##STR6## and where R4 is selected from hydrogen, C1 -C12 alkyl, phenyl or substituted phenyl.
Most preferred are compounds of formula (I) wherein the acidic group is carboxyl.
Also preferred are compounds of formula (I) wherein the divalent linking group --(La)-- has from 4 to 8 chain atoms and most preferably 5 or 6 chain atoms. Particularly preferred are compounds of Formula (I) wherein the divalent linking group, --(La)--, is selected from the following formulae: ##STR7##
A preferred subset of Formula (I) polyhydronorharman compounds which inactivate TXA2 synthase in human blood platelets and other cells is represented by Formula (II) and pharmacologically acceptable salts, solvates, or prodrugs thereof; ##STR8## wherein;
R1 is a radical at position 5, 6, 7, and 8 where each R1 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 alkoxy, C4 -C8 cycloalkyl, C1 -C12 halogenated alkyl, C1 -C12 hydroxylated alkyl, C1 -C12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C1 -C6 alkenyl, C1 -C6 alkynyl, C1 -C6 alkylthio, acyl, C1 -C6 alkoxy, or C1 -C6 alkylsulfonyl;
R2 is a radical at position 1, 3 or 4 where each R2 is independently selected from hydrogen, hydroxy, halo, cyano, sulfo, nitro, amino, substituted amino, carboxyl, acyl, carbamyl, carbonyl, alkoxycarbonyl, aryl, aryloxy, C1 -C12 alkyl, C2 -C12 alkenyl, C2 -C12 alkynyl, C1 -C12 alkoxy, C4 -C8 cycloalkyl, C1 -C12 halogenated alkyl, C1 -C12 hydroxylated alkyl, C1 -C12 substituted phenyl, the phenyl of which may optionally be substituted by alkyl, halo, hydroxy, C1 -C6 alkenyl, C1 -C6 alkynyl, C1 -C6 alkylthio, acyl, C1 -C6 alkoxy, or C1 -C6 alkylsulfonyl;
(La) is a divalent linking group containing from 4 to 6 chain atoms; and
A is an acidic group.
Preferred compounds of formula (II) are those wherein each R1 is hydrogen and/or each R2 is hydrogen, and A is carboxyl.
A preferred subset of Formula (II) polyhydronorharman compounds which inactivate TXA2 synthase in human blood platelets and other cells is represented by Formula (III) and pharmacologically acceptable salts or prodrugs thereof. ##STR9## wherein;
p is an integer 4 or 5.
Specific preferred compounds and all pharmaceutically acceptable salts, solvates and prodrug derivatives thereof which are illustrative of the compounds of the invention include the following:
(a) ethyl 5,6,7,8-tetrahydro-β-carboline-1-pentanoate,
(b) ethyl 5,6,7,8-tetrahydro-β-carboline-1-hexanoate,
(c) ethyl 5,6,7,8-tetrahydro-β-carboline-1-heptanoate, and
(d) mixtures of any of (a) thru (c)
The compounds of the invention possess at least one acidic functional substituent (viz., group A of Formula I) and, as such, are capable of forming salts. Representative pharmaceutically acceptable salts, include but are not limited to, the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion exchange resin.
Included within the definition of pharmaceutically acceptable salts are the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Phar. Sci., 66: 1-19 (1977)).
In those instances where the compounds of the invention contain a basic group(s) they may be reacted with suitable organic or inorganic acids to form salts such as acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, chloride, edetate, edisylate, estolate, esylate, fluoride, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, bromide, chloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, malseate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, palmitate, pantothenate, phosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, tosylate, trifluoroacetate, trifluoromethane sulfonate, and valerate.
The compounds of the formula (I) can also be in the form of zwitterions, since they contain both acidic and basic functionality and are capable of self-protonation.
Certain compounds of the invention possess one or more chiral centers and may thus exist in optically active forms. Likewise, when the compounds contain an alkenyl or alkenylene group there exists the possibility of cis- and trans- isomeric forms of the compounds. The R- and S- isomers and mixtures thereof, including racemic mixtures as well as mixtures of cis- and trans- isomers, are contemplated by this invention. Additional asymmetric carbon atoms can be present in a substituent group such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the invention. If a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods.
Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vive. Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine. Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters.
This invention also provides pharmaceutical formulations comprising a novel compound as described in the preceding Section I or a pharmaceutically acceptable salt or prodrug thereof.
For the pharmaceutical formulations any suitable carrier known in the art can be used. In such a formulation, the carrier may be a solid, liquid, or mixture of a solid and a liquid. Solid form formulations include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel compound of this invention. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa butter.
Sterile liquid form formulations include suspensions, emulsions, syrups and elixirs.
The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. The active ingredient can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol. Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
Preferably the pharmaceutical formulation is in unit dosage form. The unit dosage form can be a capsule or tablet itself, or the appropriate number of any of these. The quantity of active ingredient in a unit dose of composition may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration.
The formulations according to the invention may be made for oral, parenteral or rectal administration or in a form suitable for administration by inhalation or insufflation, either through the mouth or nose.
The following pharmaceutical formulations 1 thru 8 are illustrative only and are not intended to limit the scope of the invention in any way. "Active ingredient," refers to a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
Hard gelatin capsules are prepared using the following ingredients:
______________________________________ Quantity (mg/capsule) ______________________________________ Active ingredient 250 Starch, dried 200 Magnesium stearate 10 Total 460 mg ______________________________________
A tablet is prepared using the ingredients below:
______________________________________ Quantity (mg/tablet) ______________________________________ Active ingredient 250 Cellulose, microcrystalline 400 Silicon dioxide, fumed 10 Stearic acid 5 Total 665 mg ______________________________________
The components are blended and compressed to form tablets each weighing 665 mg
An aerosol solution is prepared containing the following components:
______________________________________ Weight ______________________________________ Active ingredient 0.25 Ethanol 25.75 Propellant 22 (Chlorodifluoromethane) 74.00 Total 100.00 ______________________________________
The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30° C. and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.
Tablets, each containing 60 mg of active ingredient, are made as follows:
______________________________________ Active ingredient 60 mg Starch 45 mg Microcrystalline cellulose 35 mg Polyvinylpyrrolidone (as 10% solution in water) 4 mg Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg Talc 1 mg Total 150 mg ______________________________________
The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Capsules, each containing 80 mg of active ingredient, are made as follows:
______________________________________ Active ingredient 80 mg Starch 59 mg Microcrystalline cellulose 59 mg Magnesium stearate 2 mg Total 200 mg ______________________________________
The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
Suppositories, each containing 225 mg of active ingredient, are made as follows:
______________________________________ Active ingredient 225 mg Saturated fatty acid glycerides 2,000 mg Total 2,225 mg ______________________________________
The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.
Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:
______________________________________ Active ingredient 50 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 ml Benzoic acid solution 0.10 ml Flavor q.v. Color q.v. Purified water to total 5 ml ______________________________________
The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
An intravenous formulation may be prepared as follows:
______________________________________ Active ingredient 100 mg Isotonic saline 1,000 ml ______________________________________
The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute. The pharmaceutical formulations of the invention inactivate TXA2 synthase in human blood platelets and other cells.
The compounds of the invention act as thromboxane synthase inhibitors and are advantageously combined with other agents having different modes of action to give multi-mode pharmaceutical compositions. The resultant combination of ingredients may be used as Active Ingredient in the pharmaceutical formulations described in Section II, above. Thus, an Active Ingredient (for multi-mode pharmaceutical formulations) may be formed by combining the compounds of this invention (as represented by Formulae I, II, and III) with therapeutic agents selected from one or more of the following classes:
a) thrombolytic agents;
b) angiotensin converting enzyme inhibitors;
c) thromboxane receptor antagonists.
Examples of thrombolytic agents (a) are tissue plasminogen activator (t-PA) and streptokinase. These agents would be preferably used in combination with the compounds of the invention for cardiovascular indications.
Angiotensin converting enzyme inhibitors (b) (ACE inhibitors) such as captopril, (1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline would be preferably used in combination with the compounds of the invention for renal indications such as diabetic nephropathy.
Examples of thromboxane receptor antagonists (c) are Vapiprost (Glaxo) and S-1452™ compound (CAS Reg. No.132747-47-8); (5-Heptanoic acid, 7-[3-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]-calcium salt (2:1), [1R-[1α,2α(Z),3β,4β]]; and VAPIPROST™ compound (CAS Reg. No. 87248-13-3); [1R-[1α(Z), 2β,3β5α]]-(+)-7-[5-[(1,1'-Biphenyl)-4-ylmethoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid hydrochloride; and Bay-u-3405™ compound (CAS Reg. No.116649-85-5); (9H-Carbazole-9-propanoic acid, 3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro, (R)-. These antagonists would preferably be used in combination with the compounds of the invention for cardiovascular and renal indications. Combinations of the compounds of the invention with thromboxane receptor antagonist (TRA) is a preferred aspect of this invention, because the (TRA) blocks the activity of prostaglandin H2 which is enhanced by the thromboxane synthase inhibitor compounds of the invention (represented by formulae I, II, and III).
The relative proportions of ingredients (weight ratio of compounds of the invention to therapeutic agent) will generally be in the range of from 1 to 1000 to 1000 to 1 and is readily determined by combining dosages of the ingredients in weights known to be pharmaceutically effective.
Multi-mode pharmaceutical composition may be formed by admixing the compounds of the invention with one or more classes of therapeutic agent (a), (b), or (c) listed above. Alternatively, each ingredient, (i) the compound of the invention, and (ii) the selected therapeutic agent may be packaged together, for example in a tablet having two parts, so their administration to the patient is concurrent.
This invention is a method for inhibiting thromboxane production which comprises administering to a mammalian host (e.g. human) an effective amount of the novel compounds for formulae (I), (II), or (III). The treatment of a mammal with the compounds of the invention may be for either therapeutic and/or prophylactic purposes.
A preferred method of the invention for inhibiting thromboxane production is administration to a mammal of the pharmaceutical formulations of the invention described in Section II, above, or the multi-mode pharmaceutical formulations described in Section III, above.
A specific dose of a compound of the invention administered to obtain therapeutic and/or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the route of administration and the condition being treated. A typical daily dose will contain a non-toxic dosage level of compound of from about 0.01 mg/kg to about 50 mg/kg of body weight. Preferred daily doses generally will be from about 0.05 mg/kg to about 20 mg/kg.
This invention is also an improved method of conducting angioplasty by administering before and/or during the angioplasty the thrombosis preventing novel compounds of formulae (I), (II) or (III).
This invention is a method for the prevention or treatment of a first or recurrent myocardial infarction or a first or recurrent stroke in a human comprising administering to the human in an amount effective for prevention or treatment of a first or recurrent myocardial infarction for first or recurrent stroke, a combination of active ingredients comprising the compounds of formulae (I), (II) or (III) or a pharmaceutically acceptable salt or prodrug thereof.
Scheme 1 is an illustrative reaction sequence for preparation of 5,6,7,8-tetrahydro-β-carboline-1-alkanoic acids. ##STR10## Fuming nitric and sulfuric acids are employed to nitrate 4-hydroxypyridine to produce 4-hydroxy-3-nitropyridine. The 4-hydroxy-3-nitropyridine is converted to 4-chloro-3-nitropyridine by heating with PC15 and POCl3. Reacting 4-chloro-3-nitropyridine with 1-(1-pyrrolidino)cyclohexene in CH2 C12 with added triethylamine produces 2-(2-nitro-4-pyridyl)cyclohexanone which, upon hydrogenation, provides 5,6,7,8-tetrahydro-β-carboline. Deprotonation of the 5,6,7,8-tetrahydro-β-carboline with base and subsequent alkylation with a suitable alkyl ω-halo-alkanoate gives alkyl 5,6,7,8-tetrahydro-β-carboline-1alkanoate which may then be hydrolyzed with base to provide the corresponding 5,6,7,8-tetrahydro-β-carboline-1-alkanoic acid.
The following Examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Centigrade and all parts wherever given are parts by weight unless otherwise indicated.
To a solution of 4-hydroxypyridine (101.8 g, 0.981 mole, 90%) in water (1L) at ice bath temperature was added concentrated nitric acid (182 ml, 4.04 mole). The ice bath was removed and the stirring solution permitted to warm to room temperature then stirred at room temperature for 30 minutes. The solution was then concentrated under reduced pressure by half and refrigerated. The precipitated 4-hydroxypyridinium nitrate was dried in vacuo before it was added to a solution of fuming sulfuric acid (120ml) and fuming nitric acid (156 ml) at ice bath temperatures. This solution was stirred at room temperature overnight (16 hours) then at 85°-95° C. for 5.5 hours, permitted to cool to room temperature then poured over ice (650 g). The resulting precipitate was collected and dried, recrystallized from ethanol/water and dried in vacuo to leave 78.8 g (57.3%) product as pale yellow crystals with melting point 278°-280° C.
Analysis for C5 H4 N2 O3 : Calculated C, 42.87; H, 2.88; N, 19.99 Found C, 43.08; H, 2.94; N, 19.97 ##STR12## Preparation of 4-chloro-3-nitropyridine.
4-hydroxy-3-nitropyridine (24.6 g, 175 mmole), phosphorus pentachloride (40.0 g, 192 mmole), and phosphorus oxychloride (3.0 ml, 32 mmol) were combined and heated via oil bath. The reaction solution was stirred at oil bath temperatures of 135°-140° C. for 3 hours before the phosphorus oxychloride was distilled off at atmospheric pressure. Relatively low-boiling materials were removed from the reaction vessel via bulb-to-bulb distillation (Aldrich kugelrohr). The material obtained was vacuum distilled (100°-110° C., 3-10 mm) to provide 18.27 g (66%) product as yellow liquid (solidifies in ice bath). NMR. 9.21 ppm (singlet, 1H); 8.80 ppm (doublet, 1H); 7.91 ppm (doublet, 1H). ##STR13## Preparation of 2-(2-nitro-4-pyridyl)cyclohexanone.
To a stirring solution of 4-chloro-3-nitropyridine (9.2 g, -50 mmole) in CH2 Cl2 (100 ml) under nitrogen were added triethylamine (5.0 ml, 36 mmole) and 1-(1-pyrrolidino) cyclohexene (31 ml, 170 mmole, 90%). The reaction solution was stirred at room temperature for 6 days, then concentrated under reduced pressure and cold in HCl added with stirring until pH=7. The resulting mixture was extracted with ether (2×250 ml) and the combined organic phases washed with brine (40 ml), dried (MgSO4), and concentrated under reduced pressure to 18 g of dark oil. Chromatography (SiO2, step gradient elution from 10% ethyl acetate in hexane to 50% ethyl acetate in hexane) and recrystallization (ether/hexane) provided 5.1 g (46%) of desired product as off-white prisms with melting point 68.5°-70.5° C. Additional purification (chromatography/recrystallization) provided material with melting point 69°-71° C.
Analysis. for C11 H12 N2 O3 : Calculated C, 59.99; H, 5.49; N, 12.72 Found C, 59.69; H, 5.56; N, 12.73 ##STR14## Preparation of 5,6,7,8-tetrahydro-β-carboline.
A mixture of 2-(2-nitro-4-pyridyl)cyclohexanone (2.1 g, 9.5 mmole), 5% palladium on carbon (1.0 g, 0.47 mmole) and ethanol (200 ml, 0.44% toluene) was agitated under 40 psi (2.76×105 Pa) hydrogen pressure for 3 hours before the reaction mixture was filtered and the filtrate concentrated under reduced pressure. Chromatography of the residue (florisil, step gradient elution from ethyl acetate to 15% methanol in ethyl acetate) followed by recrystallization of the highest Rf band (from ethyl acetate) produced 0.87 g (48%) desired product as beige needles, melting point 200°-201° C.
Analysis. for C11 H12 N2 : Calculated C, 76.71; H, 7.02; N, 16.26 Found C, 76.42; H, 7.02; N, 16.25. ##STR15## Preparation of ethyl 5,6,7,8-tetrahydro-β-carboline-1-hexanoate.
To a suspension of NaH (0.20 g, 5.0 mmole, 60% dispersion in oil) in anhydrous DMF (5 ml) under nitrogen was added dropwise (over 30 min) a solution of 5,6,7,8-tetrahydro-β-carboline (0.74 g, 4.3 mmole) in anhydrous DMF (15 ml). The reaction mixture was stirred at room temperature until solution was achieved (30 min), whereupon a solution of ethyl 6-iodohexanoate (1.6 g, 5.9 mmole) in anhydrous DMF (4 ml) was added at such a rate that the internal temperature did not exceed 35° C. The reaction solution was then stirred at room temperature under nitrogen for 3.5 hours before it was added to ice water (100 ml) and extracted with ethyl acetate (2×75 ml). The combined organic phases were washed with brine (35 ml), dried (MgSO4), and concentrated in vacuo to a brown oil. Chromatography provided 0.58 g (43%) desired product as yellow oil.
Analysis. for C19 H26 N2 O2 : Calculated C, 72.58; H, 8.33; N, 8.91 Found C, 72.30; H, 8.38; N, 8.92 ##STR16## Preparation of 5,6,7,8-tetrahydro-β-carboline-1-hexanoic acid hydrochloride salt.
To a solution of ethyl 5,6,7,8-tetrahydro-β-carboline-1-hexanoate (0.55 g, 1.7 mole) in ethanol (15 ml) was added 5N NaOH (3.0 ml, 15 mole). The reaction solution was stirred at room temperature for 3 hours before it was concentrated under reduced pressure and the residue dissolved in water (5.0 ml). Acidification of this aqueous solution with 5N HCl resulted in the formation of a colorless crystalline precipitate which, after drying, left 0.35 g (64%) desired product with melting point 264°-266° C. (dec).
Analysis for C17 H23 C1 N2 O2 Calculated C, 63.25; H, 7.18; N, 8.68 Found C, 62.98; H, 7.22; N, 8.60
The ability of the compound of the present invention to be an effective thromboxane synthase inhibitor was evaluated in the following Thromboxane Synthase Inhibition (TSI) Assay with the results shown in Table 1 below:
TABLE 1 ______________________________________ Compound of Example 1 Part F (μM) *Serum TXB.sub.2 (ng/ml) ______________________________________ 0 (vehicle) 375 ± 85.8 0.01 312 ± 88.1 0.1 170 ± 57.5 1 22.4 ± 4.3 10 5.8 ± 2.2 ______________________________________ *Mean ± SE, n = 3
The test compound, 5,6,7,8-tetrahydro-β-carboline-1-hexanoic acid hydrochloride salt, (the compound of Example 1, Part F) was dissolved in dimethylsulfoxide at varying concentrations. The compound solutions and dimethylsulfoxide alone (vehicle) were incubated with fresh whole human blood that had been anticoagulated with 0.38% trisodium citrate, for 30 minutes at 37° C. After 30 minutes, 0.025 ml of 0.5M calcium chloride solution was added to each 1 ml of blood and further incubated for one hour at 37° C. Serum was prepared by centrifugation of the blood at 2000× g for 15 minutes in a Beckman table top centrifuge. Serum TXB2 and 6-keto-PGF1a, the stable metabolites of and markers of synthesis of TXA2 and prostacyclin respectively, were measured by radioimmunoassay by commonly used test methods (see, Refs.,1 & 2 below). Results from the radioimmunoassay of TXB2 are shown in Table 1 and indicate the dose-dependent potency of the compound of Example 1, Part F as a thromboxane synthase inhibitor. These data were used to calculate the IC50 (concentration of compound required to reduce thromboxane generation to 50% of that obtained with vehicle alone) which for the compound of Example 1, Part F was 81±26 nH (mean ±SE, n=3).
Data determined from the radioimmunoassay of serum 6-keto-PGF1a (reflecting prostacyclin generation) allowed a determination of the specificity of the compound of Example 1, Part F for the inhibition of thromboxane synthase versus cyclooxygenase and prostacyclin synthase as indicated by the serum levels of 6-keto-PGF1a. These values decrease in the presence of a non-specific inhibitor (e.g., aspirin) but are unchanged or increased by specific TSI. The data in Table 2 documents the expected dose-dependent stimulatory effect of the compound of Example 1, Part F on human serum 6-keto-PGF1a levels and confirm the specific TSI by the compound of Example 1, Part F.
TABLE 2 ______________________________________ Compound of Example 1 Part F (μM) Serum 6-keto-PGF.sub.1a *(ng/ml) ______________________________________ 0 (vehicle) 1.6 ± 0.2 0.01 1.9 ± 0.1 0.1 2.8 ± 0.1 1 3.2 ± 0.1 10 3.4 ± 0.2 ______________________________________ *Mean ± SE, n = 3
The oral activity of the compound of Example 1, Part P was established by treating rats via the oral route with solutions of the compound and one hour later collecting blood. The blood was allowed to clot in glass tubes for 1 hour at 37° C. Serum was collected after sedimentation of the clot by centrifugation at 2000× g for 15 minutes in a Beckman table top centrifuge. The levels of TXB2 were measured in the serum by radioimmunoassay. Decreased levels of TXB2 indicate the presence of compound in the blood resulting from oral absorption. The results of these experiments are shown in Table 3 and document the availability of the compound by the oral route of administration and the dose-dependency of the desired inhibitory effect on serum TXB2.
TABLE 3 ______________________________________ Administered Dose of Compound of Example 1 Serum TXB.sub.2 Part F (mg/kg, p.o.) *(ng/ml) ______________________________________ 0 298 ± 1.7 1 137 ± 12 10 10.7 ± 2.0 ______________________________________ *Mean ± SE, n = 3
Ref. 1. Sors, H., Pradelles, P and Dray, F. Prostaglandins, 16:277, 1978
Ref. 2. Dray, et al. Advances in Prostaglandin and Thromboxane Research 6:167, 1980.
Claims (7)
1. A polyhydronorharman compound which inactivates TXA2 synthase in human blood platelets and other cells, said compound represented by the formula (III): ##STR17## wherein; p is an integer 4 or 5.
2. A compound selected from the group consisting of the following:
(a) ethyl 5,6,7,8-tetrahydro-β-carboline-1-pentanoate,
(b) ethyl 5,6,7,8-tetrahydro-β-carboline-1-hexanoate,
(c) ethyl 5,6,7,8-tetrahydro-β-carboline-1-heptanoate, and
(d) mixtures of any of (a) thru (c);
or a pharmaceutically acceptable salt, solvate and prodrug derivative thereof.
3. A pharmaceutical formulation comprising an effective amount of the compound of claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.
4. A polyhydronorharman compound, or a pharmacologically acceptable salt, solvate, or aliphatic ester prodrug thereof, which compound inactivates TXA2 synthase in mammalian human blood platelets and other cells, and said compound is represented by the formula (II): ##STR18## wherein; R1 is a radical at position 5, 6, 7, and 8 where each R1 is independently selected from hydrogen, hydroxy, halogen, C1 -C12 alkyl, C1 -C12 alkoxy, and C4 -C8 cycloalkyl,
R2 is hydrogen;
(La) is a divalent linking group selected from the following formulae: ##STR19## and A is an acidic group selected from the following: ##STR20## and where R4 is selected from hydrogen, C1 -C12 alkyl, phenyl or substituted phenyl.
5. A polyhydronorharman compound which inactivates TXA2 synthase in mammalian human blood platelets and other cells, said compound represented by the formula (II): ##STR21## wherein; R1 and R2 are hydrogen;
(La) is a divalent linking group selected from ##STR22## and A is a carboxyl group or a pharmacologically acceptable salt, solvate, or ethyl ester prodrug thereof.
6. A pharmaceutical formulation comprising an effective amount of the compound of claim 5 together with a pharmaceutically acceptable carrier or diluent therefor.
7. A method of inactivating the TXA2 synthase in mammalian blood platelets and other cells by administering to a mammal an effective dose of a polyhydronorharman compound of claim 5.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/189,213 US5550118A (en) | 1994-01-31 | 1994-01-31 | Polyhydronorharman synthase inhibitors |
EP95300397A EP0665227A1 (en) | 1994-01-31 | 1995-01-23 | Polyhydronorharman synthase inhibitors |
CA002140953A CA2140953A1 (en) | 1994-01-31 | 1995-01-24 | Polyhydronorharman synthase inhibitors |
JP7011808A JPH07223954A (en) | 1994-01-31 | 1995-01-27 | Polyhydronorharman synthetic enzyme inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/189,213 US5550118A (en) | 1994-01-31 | 1994-01-31 | Polyhydronorharman synthase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US5550118A true US5550118A (en) | 1996-08-27 |
Family
ID=22696408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/189,213 Expired - Fee Related US5550118A (en) | 1994-01-31 | 1994-01-31 | Polyhydronorharman synthase inhibitors |
Country Status (4)
Country | Link |
---|---|
US (1) | US5550118A (en) |
EP (1) | EP0665227A1 (en) |
JP (1) | JPH07223954A (en) |
CA (1) | CA2140953A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253891A1 (en) * | 2000-09-12 | 2004-12-16 | Schierenbeck Alan W. | Composite structure for protective garment |
US20050101623A1 (en) * | 2003-07-23 | 2005-05-12 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
US20050192327A1 (en) * | 1997-10-17 | 2005-09-01 | Montgomery Hugh E. | Use of inhibitors of the renin-angiotensin system |
CN103880740A (en) * | 2014-04-14 | 2014-06-25 | 西华大学 | Synthesis of 4-nitro-3-hydroxy-2-picolinic acid |
CN109912695A (en) * | 2017-12-12 | 2019-06-21 | 首都医科大学 | Seven ring aldehyde of RGDV modification, preparation, anti-thrombus activity and application |
CN110551176A (en) * | 2018-06-04 | 2019-12-10 | 首都医科大学 | LDV modified S, R-heptacyclic aldehyde, and synthesis, activity and application thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3724988B2 (en) * | 1999-07-30 | 2005-12-07 | 信越化学工業株式会社 | Novel silicone compound and cosmetic comprising the same |
EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
SG11201504622PA (en) | 2012-12-20 | 2015-07-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
EA201690230A1 (en) | 2013-09-06 | 2016-07-29 | Инсепшн 2, Инк. | TRIAZOLONE COMPOUNDS AND THEIR APPLICATIONS |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2850501A (en) * | 1956-07-30 | 1958-09-02 | Searle & Co | Basic esters of 9-pyrid (3, 4-b) indole alkanoic acid |
US4855295A (en) * | 1985-10-04 | 1989-08-08 | Schering Aktiengesellschaft | Tetrahydro-beta-carbolines, and their use as drugs |
US5066649A (en) * | 1989-01-19 | 1991-11-19 | Duphar International Research B.V. | 8,9-annelated-1,2,3,4-tetrahydro-β-carboline derivatives |
US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536505A (en) * | 1983-05-17 | 1985-08-20 | Ciba-Geigy Corporation | Certain N-(pyridyl) indoles |
DE4308788A1 (en) * | 1993-03-18 | 1994-09-22 | Bayer Ag | Hetero-tricyclic-substituted phenyl-cyclohexane-carboxylic acid derivatives |
-
1994
- 1994-01-31 US US08/189,213 patent/US5550118A/en not_active Expired - Fee Related
-
1995
- 1995-01-23 EP EP95300397A patent/EP0665227A1/en not_active Withdrawn
- 1995-01-24 CA CA002140953A patent/CA2140953A1/en not_active Abandoned
- 1995-01-27 JP JP7011808A patent/JPH07223954A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2850501A (en) * | 1956-07-30 | 1958-09-02 | Searle & Co | Basic esters of 9-pyrid (3, 4-b) indole alkanoic acid |
US4855295A (en) * | 1985-10-04 | 1989-08-08 | Schering Aktiengesellschaft | Tetrahydro-beta-carbolines, and their use as drugs |
US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
US5066649A (en) * | 1989-01-19 | 1991-11-19 | Duphar International Research B.V. | 8,9-annelated-1,2,3,4-tetrahydro-β-carboline derivatives |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003679B2 (en) | 1997-10-17 | 2011-08-23 | ArkTherapeutics Group, plc | Use of inhibitors of the renin-angiotensin system |
US7998953B2 (en) | 1997-10-17 | 2011-08-16 | Ark Therapeutics Group, p.l.c. | Use of inhibitors of the renin-angiotensin system |
US20060217429A1 (en) * | 1997-10-17 | 2006-09-28 | Montgomery Hugh E | Use of inhibitors of the renin-angiotensin system |
US20090069348A1 (en) * | 1997-10-17 | 2009-03-12 | Hugh Edward Montgomery | Use of Inhibitors of the Renin-Angiotensin System |
US20050192327A1 (en) * | 1997-10-17 | 2005-09-01 | Montgomery Hugh E. | Use of inhibitors of the renin-angiotensin system |
US20050192326A1 (en) * | 1997-10-17 | 2005-09-01 | Hugh Edward Montgomery | Use of inhibitors of the renin-angiotensin system |
US20040253891A1 (en) * | 2000-09-12 | 2004-12-16 | Schierenbeck Alan W. | Composite structure for protective garment |
US20050101623A1 (en) * | 2003-07-23 | 2005-05-12 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
US20050143371A1 (en) * | 2003-07-23 | 2005-06-30 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
US20050137220A1 (en) * | 2003-07-23 | 2005-06-23 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
CN103880740A (en) * | 2014-04-14 | 2014-06-25 | 西华大学 | Synthesis of 4-nitro-3-hydroxy-2-picolinic acid |
CN103880740B (en) * | 2014-04-14 | 2016-02-17 | 西华大学 | The synthesis of 4-nitro-3-hydroxyl-2-pyridine carboxylic acid |
CN109912695A (en) * | 2017-12-12 | 2019-06-21 | 首都医科大学 | Seven ring aldehyde of RGDV modification, preparation, anti-thrombus activity and application |
CN109912695B (en) * | 2017-12-12 | 2021-02-12 | 首都医科大学 | RGDV-modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof |
CN110551176A (en) * | 2018-06-04 | 2019-12-10 | 首都医科大学 | LDV modified S, R-heptacyclic aldehyde, and synthesis, activity and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JPH07223954A (en) | 1995-08-22 |
CA2140953A1 (en) | 1995-08-01 |
EP0665227A1 (en) | 1995-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4943587A (en) | Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition | |
US5468898A (en) | Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity | |
US5604236A (en) | Beta-carboline thromboxane synthase inhibitors | |
US5919932A (en) | Biphenylamide derivatives as 5HT1D antagonists | |
JPH07188165A (en) | 5,6-bicyclic glycoprotein iib/iiia antagonist | |
AU653007B2 (en) | Pyrazolopyridine compound and processes for preparation thereof | |
JP6811233B2 (en) | Cyclic compounds useful as modifiers of TNF alpha | |
JPH01316363A (en) | Piperazine derivative and salt thereof | |
US5550118A (en) | Polyhydronorharman synthase inhibitors | |
US5468757A (en) | 6-azaindole thromboxane synthase inhibitors | |
EP0227241B1 (en) | Medicinal indole and indazole keto sulphone derivatives | |
US5747477A (en) | Azo derivatives of 5-aminosalicylic acid | |
US4590199A (en) | Antihistaminic 2-(amino ethylamino) pyridines | |
US4749701A (en) | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | |
US4814345A (en) | 1-phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them | |
US4444775A (en) | Substituted imidazo[1,5-A]pyridines | |
US5137914A (en) | Sulfonylamino substituted bicyclo [2.2.1]heptane hydroxamic acid derivatives useful as pharmaceuticals | |
SK9312000A3 (en) | N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them | |
US5830902A (en) | Quinuclidine derivative having tricyclic hetero condensed ring | |
US5362879A (en) | 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation | |
DK169517B1 (en) | [Aryl] (3-pyridinyl) methanone, oxime derivatives and process for their preparation | |
AU5964899A (en) | Biphenylene lactams as prostaglandin receptor ligands | |
US4610995A (en) | Certain 1,1-diaryl-propenyl-3-(1-pyrrolidino-2-carboxylic acids, derivatives thereof and their anti-histaminic properties | |
JPH03133986A (en) | Alloyl urea | |
US4690933A (en) | Pyridylvinyl-1H tetrazole having antihistamine activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ELI LILLY AND COMPANY, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JAKUBOWSKI, JOSEPH A.;PALKOWITZ, ALAN D.;SIGMUND, SANDRA K.;REEL/FRAME:007921/0940;SIGNING DATES FROM 19940127 TO 19940131 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20080827 |